CNS Response CEO Leonard Brandt to Present at the OneMedPlace Finance Forum

COSTA MESA, CA, Jan 12 (MARKET WIRE) --
CNS Response, Inc. (OTCBB: CNSO) today announced that CEO Leonard Brandt
will be presenting at the second annual OneMedPlace Finance Forum, for
emerging medical technology companies. The conference is being held
January 13 and 14 in San Francisco, at the Sir Francis Drake Hotel,
located in San Francisco's Union Square at 450 Powell Street. Mr.
Brandt's presentation will take place Tuesday, January 13, at 1:45 p.m.

Mr. Brandt will be discussing the company's innovative technology that
produces a personalized medication report for physicians to guide
treatment of patients with difficult to treat mental illness. CNS
Response is the first company to bring a physiological-based technology
to market that helps the doctor answer the question, "What is the right
medication for my patient?" This is truly personalized medicine.

"This is an excellent venue for our company, as the Forum's goal is to
provide exposure for undiscovered companies in the healthcare sector with
market caps below $500 million," commented Brandt. "Equally important,"
added Brandt, "is the Forum's focus on companies developing and
commercializing disruptive technologies that have received limited
research coverage in the financial communities."

About CNS Response

CNS Response is a life-sciences data company whose patented system
provides treatment guidance to psychiatrists and other physicians for
patients with behavioral (mental or addictive) disorders. This technology
allows CNS Response to create and provide simple reports ("rEEG(R)
Reports") that specifically guide physicians to treatment strategies
based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction
with a normative database and a proprietary clinical (symptomatic)
database to identify the following: (1) medication classes most likely to
be needed; and (2) medications within these classes with the most
probable treatment potential for each patient. Reports are provided to
physicians in a relationship analogous to that of a reference laboratory.
Prospective, retrospective and field studies of treatment-resistant
patients have reported treatment success of 70% or greater in managed
care, outpatient psychiatric and residential substance abuse clinical
settings.

In addition to providing analytical support to physicians, CNS Response is
also an aid to pharmaceutical developers, who can use rEEG to (1) stratify
study populations to improve the success of FDA clinical trials; (2)
provide insight on effective therapeutic dosing of investigational drugs;
(3) identify additional indications for psychiatric medications; (4)
provide insight into effective drug combinations; and (5) discover
opportunities for decision analytics and support. In addition to these
applications, CNS Response continues to investigate the use of rEEG
analysis for development of proprietary pharmaceutical opportunities.
Visit the company's website at www.cnsresponse.com.

Contact:
Investor and Media Relations:
Marty Tullio
McCloud Communications LLC
949.553.9748
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-